In recent years, the incidence of cancer is increasing. But most current therapeutic regimens for cancer involve the systemic administration of antineoplastic agents that are well known to cause toxic side effects to healthy normal cells and tissue. Most of the anti-cancer drugs are characterized by a low therapeutic index (TI), a wide range of organ toxicities (especially in the liver) and large individual differences in pharmacokinetic parameters, of which are affected by not only the tumor sensitivity to drugs but also the patient's genetic background (such as liver drug enzyme CYP and drug ATP binding and transporter polymorphism), patient characteristics (such as treatment compliance) and environmental factors. Therefore, along with prognosis, studies on blood concentration monitoring which plays an important role in the efficacy and safety of anti-cancer drug treatment, can potentially help reducing drug toxicity and improving the therapeutic effect.
In this Research Topic, we mainly focus on the relationship between the blood concentration of anti-cancer drugs and their efficacy and toxicity, to improve curative effect and reduce drug toxicity. Furthermore, we also aim at exploring the mechanisms of anti-cancer drug-induced toxicology, as well as polymorphisms of drug-metabolizing enzymes, transporters, targets, and genetic and environmental factors, that affect blood drug concentration and guide clinical dosage adjustment. We hope to deep dive into cancer pathogenesis and recent treatment advances.
We encourage authors to submit Original Research, Systematic Review, Review, Opinion, and Perspective articles, in the following subtopics, but not limited to:
• Anti-cancer drugs induced disease and the potential toxicity mechanism.
• The correlation between concentration, efficacy and toxicity.
• Polymorphisms of drug-metabolizing enzymes, transporters, targets, and genetic and environmental factors.
• The optimal concentration range of anti-cancer targeted drugs for cancer patients.
• The study of population pharmacokinetic model and scientific individualized treatment plan.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
In recent years, the incidence of cancer is increasing. But most current therapeutic regimens for cancer involve the systemic administration of antineoplastic agents that are well known to cause toxic side effects to healthy normal cells and tissue. Most of the anti-cancer drugs are characterized by a low therapeutic index (TI), a wide range of organ toxicities (especially in the liver) and large individual differences in pharmacokinetic parameters, of which are affected by not only the tumor sensitivity to drugs but also the patient's genetic background (such as liver drug enzyme CYP and drug ATP binding and transporter polymorphism), patient characteristics (such as treatment compliance) and environmental factors. Therefore, along with prognosis, studies on blood concentration monitoring which plays an important role in the efficacy and safety of anti-cancer drug treatment, can potentially help reducing drug toxicity and improving the therapeutic effect.
In this Research Topic, we mainly focus on the relationship between the blood concentration of anti-cancer drugs and their efficacy and toxicity, to improve curative effect and reduce drug toxicity. Furthermore, we also aim at exploring the mechanisms of anti-cancer drug-induced toxicology, as well as polymorphisms of drug-metabolizing enzymes, transporters, targets, and genetic and environmental factors, that affect blood drug concentration and guide clinical dosage adjustment. We hope to deep dive into cancer pathogenesis and recent treatment advances.
We encourage authors to submit Original Research, Systematic Review, Review, Opinion, and Perspective articles, in the following subtopics, but not limited to:
• Anti-cancer drugs induced disease and the potential toxicity mechanism.
• The correlation between concentration, efficacy and toxicity.
• Polymorphisms of drug-metabolizing enzymes, transporters, targets, and genetic and environmental factors.
• The optimal concentration range of anti-cancer targeted drugs for cancer patients.
• The study of population pharmacokinetic model and scientific individualized treatment plan.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
